Ken Griffin Recursion Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 299,300 shares of RXRX stock, worth $2.21 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

299,300

Previous 256,400 16.73%

Holding current value

$2.21 Million

Previous $1.92 Million 2.55%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$5.92 - $8.6 $3.02 Million - $4.39 Million	-510,856 Reduced 68.56%	234,223 $1.54 Million
Q2 2024 Aug 14, 2024	BUY	$7.35 - $10.05 $2.97 Million - $4.07 Million	404,705 Added 118.9%	745,079 $5.59 Million
Q1 2024 May 15, 2024	BUY	$9.13 - $15.52 $2.77 Million - $4.72 Million	303,880 Added 832.68%	340,374 $3.39 Million
Q4 2023 Feb 14, 2024	SELL	$5.09 - $10.79 $1.36 Million - $2.88 Million	-266,596 Reduced 87.96%	36,494 $359,000
Q3 2023 Nov 14, 2023	SELL	$6.59 - $15.86 $2.86 Million - $6.89 Million	-434,668 Reduced 58.92%	303,090 $2.32 Million
Q2 2023 Aug 14, 2023	BUY	$4.56 - $9.94 $603,028 - $1.31 Million	132,243 Added 21.84%	737,758 $5.51 Million
Q1 2023 May 15, 2023	SELL	$6.42 - $9.64 $1.06 Million - $1.6 Million	-165,635 Reduced 21.48%	605,515 $4.04 Million
Q4 2022 Feb 14, 2023	BUY	$7.16 - $12.7 $1.93 Million - $3.42 Million	269,280 Added 53.66%	771,150 $5.95 Million
Q3 2022 Nov 14, 2022	BUY	$7.83 - $13.6 $1.52 Million - $2.65 Million	194,498 Added 63.28%	501,870 $5.34 Million

Others Institutions Holding RXRX

# of Institutions

286

Shares Held

242M

Call Options Held

1.35M

Put Options Held

2.32M

View Full List

About RECURSION PHARMACEUTICALS, INC.

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $1.33B
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

More about RXRX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account